Inicio › Leucemia mielógena aguda › Massachusetts › Boston
Ensayos clínicos de Leucemia mielógena aguda en Boston, MA
44 estudios para Leucemia mielógena aguda buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ivosidenib as Post-HSCT Maintenance for AML
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Tufts Medical Center, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
ReclutandoFase 1/2
- Dana-Farber Cancer Center, Boston
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutandoFase 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
ReclutandoFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
ReclutandoFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
ReclutandoFase 1Se aceptan voluntarios sanos
- Brigham and Women's Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
ReclutandoFase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
ReclutandoEstudio observacional
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
ReclutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutandoFase 2/3
- Dana-Farber Cancer Institute, Boston
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Ziftomenib Maintenance Post Allo-HCT
ReclutandoFase 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
ReclutandoFase 1
- Massachusetts General Hospital, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
ReclutandoFase 2Se aceptan voluntarios sanos
- DFCI/BWH Brigham and Women's Hospital, Boston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
ReclutandoFase 1
- DFCI, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
ReclutandoFase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Novel Digital Application for Patients With Acute Leukemia
Reclutando
- Massachusetts General Hospital (MGH), Boston
IS-free Treg HaploHCT
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
ReclutandoSe aceptan voluntarios sanos
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Philadelphia, PA34 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
- Washington, DC24 estudios
Otros estudios en Boston
- Cáncer de seno112 estudios
- Cáncer de pulmón de células no pequeñas90 estudios
- Cáncer (todos los tipos)85 estudios
- Cáncer metastásico63 estudios
- Cáncer del colon y del recto63 estudios
- Cáncer de pulmón62 estudios
- Cáncer de ovario61 estudios
- Cáncer de próstata59 estudios
- Depresión52 estudios
- Cáncer de endometrio50 estudios
- Fallo cardíaco44 estudios
- Cáncer de páncreas43 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.